HUP0300382A3 - 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds - Google Patents

2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds

Info

Publication number
HUP0300382A3
HUP0300382A3 HU0300382A HUP0300382A HUP0300382A3 HU P0300382 A3 HUP0300382 A3 HU P0300382A3 HU 0300382 A HU0300382 A HU 0300382A HU P0300382 A HUP0300382 A HU P0300382A HU P0300382 A3 HUP0300382 A3 HU P0300382A3
Authority
HU
Hungary
Prior art keywords
treatmetn
pyrimidines
heteroaryl
substituted
compounds
Prior art date
Application number
HU0300382A
Other languages
English (en)
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007636A external-priority patent/GB0007636D0/en
Priority claimed from GB0015117A external-priority patent/GB0015117D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of HUP0300382A2 publication Critical patent/HUP0300382A2/hu
Publication of HUP0300382A3 publication Critical patent/HUP0300382A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
HU0300382A 2000-03-29 2001-03-28 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds HUP0300382A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0007636A GB0007636D0 (en) 2000-03-29 2000-03-29 Anti-cancer compounds
GB0015117A GB0015117D0 (en) 2000-06-20 2000-06-20 Anti-cancer compounds
PCT/GB2001/001423 WO2001072745A1 (en) 2000-03-29 2001-03-28 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders

Publications (2)

Publication Number Publication Date
HUP0300382A2 HUP0300382A2 (hu) 2003-06-28
HUP0300382A3 true HUP0300382A3 (en) 2006-11-28

Family

ID=26243984

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300382A HUP0300382A3 (en) 2000-03-29 2001-03-28 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds

Country Status (11)

Country Link
US (2) US6531479B2 (hu)
EP (1) EP1274705A1 (hu)
JP (1) JP5074653B2 (hu)
CN (1) CN100355751C (hu)
AU (2) AU4262901A (hu)
CA (1) CA2401748A1 (hu)
GB (1) GB2361236B (hu)
HU (1) HUP0300382A3 (hu)
IL (1) IL151946A0 (hu)
NZ (1) NZ521068A (hu)
WO (1) WO2001072745A1 (hu)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
JP4541695B2 (ja) * 2001-06-15 2010-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとしての５−（２−アミノピリミジン−４−イル）ベンズイソキサゾール
US7870013B1 (en) * 2001-06-29 2011-01-11 Versata Development Group, Inc. Automated system and method for managing goals
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20040181066A1 (en) * 2001-08-01 2004-09-16 Fraley Mark E. Tyrosine kinase inhibitors
EA007933B1 (ru) * 2001-08-13 2007-02-27 Янссен Фармацевтика Н.В. 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
ATE381542T1 (de) * 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
CA2460909A1 (en) * 2001-09-28 2003-04-10 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
GB0123589D0 (en) * 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
BR0213792A (pt) * 2001-11-01 2004-12-07 Janssen Pharmaceutica Nv Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3)
US20050222054A1 (en) * 2002-03-27 2005-10-06 Cyclacel Limited Combination comprising a CDK inhibitor and doxorubicin
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
WO2004007754A2 (en) * 2002-07-12 2004-01-22 Rigel Pharmaceuticals, Inc. Modulators of cellular proliferation
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226582D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
EP2316831B1 (en) * 2002-11-21 2013-03-06 Novartis AG 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
SI2316831T1 (sl) * 2002-11-21 2013-07-31 Novartis Ag 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
EP1581526B1 (en) * 2002-12-18 2009-03-11 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20040235834A1 (en) * 2003-03-25 2004-11-25 Farmer Luc J. Thiazoles useful as inhibitors of protein kinases
EP1644338A1 (en) * 2003-04-01 2006-04-12 Aponetics AG 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0313511D0 (en) * 2003-06-11 2003-07-16 Cyclacel Ltd Combination
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
KR101204247B1 (ko) 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-이치환된 1ｈ-피라졸 화합물 및 그의 시클린 의존성키나제 (ｃｄｋ) 및 글리코겐 합성효소 키나제-3(ｇｓｋ-3) 조정제로서 용도
BRPI0412351A (pt) * 2003-07-30 2006-09-05 Cyclacel Ltd derivados e piridilamino-pirimidina como inibidores de proteìna quinase
AU2004261484A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP5164380B2 (ja) * 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0402653D0 (en) * 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
WO2005113550A1 (ja) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation アミノピリミジン誘導体及びその医薬としての用途
CN1956982A (zh) * 2004-05-21 2007-05-02 万有制药株式会社 具有氨基噻唑骨架的Cdk4、6选择性抑制剂
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
CN100564372C (zh) 2004-08-19 2009-12-02 帝斯曼知识产权资产管理有限公司 用于精馏高沸点的对空气和/或温度敏感的有用产品的混合物的方法
WO2006021803A2 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
GB0419416D0 (en) * 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
JP2008538544A (ja) * 2004-09-23 2008-10-30 レディ ユーエス セラピューティックス， インコーポレイテッド 新規ピリミジン化合物、それらの調製のためのプロセスおよびそれらを含む組成物
AU2005293607A1 (en) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
MX2007005125A (es) * 2004-10-28 2007-07-04 Irm Llc Compuestos y composiciones como moduladores de la senda de hedgehog.
ES2397362T3 (es) * 2004-12-17 2013-03-06 Amgen Inc. Compuestos de aminopirimidina como inhibidores de PLK
EP2395000A1 (en) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
CA2594477C (en) 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
EP1845974A1 (en) 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
WO2006093247A1 (ja) 2005-02-28 2006-09-08 Japan Tobacco Inc. Ｓｙｋ阻害活性を有する新規なアミノピリジン化合物
EP1910874A4 (en) * 2005-08-03 2009-08-05 Corning Inc FAR-UV UV TELECENTRY IMAGING SYSTEM WITH AXISYMETRIC BIREFRINGENT ELEMENT AND POLAR ORTHOGONAL POLARIZATION
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
AU2008213808B2 (en) 2007-02-06 2011-11-10 Novartis Ag PI 3-kinase inhibitors and methods of their use
WO2008129080A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
EP2137165B1 (en) 2007-04-24 2013-04-24 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
WO2008129070A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008129071A1 (en) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
BRPI0820722A2 (pt) 2007-12-20 2015-06-16 Novartis Ag Derivados de tiazol usados como inibidores de pi 3 cinases
GB0805477D0 (en) * 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
CA2849995A1 (en) 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EA035349B1 (ru) 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
CN117731786A (zh) 2013-07-12 2024-03-22 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
AU2013399092A1 (en) * 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
ES2702951T3 (es) 2014-04-04 2019-03-06 Syros Pharmaceuticals Inc Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
EP3957637B1 (en) * 2015-08-04 2023-06-28 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
WO2017147701A1 (en) 2016-03-01 2017-09-08 Ontario Institute For Cancer Research (Oicr) Inhibitors of wdr5 protein-protein binding
CN109195965B (zh) 2016-03-01 2022-07-26 普罗佩纶治疗公司 Wdr5蛋白质-蛋白质结合的抑制剂
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
CN108727363B (zh) * 2017-04-19 2020-06-19 劲方医药科技(上海)有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2023509260A (ja) 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
AR120184A1 (es) 2019-10-11 2022-02-02 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2023172957A1 (en) * 2022-03-09 2023-09-14 Prelude Therapeutics, Incorporated Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals
WO2023192801A1 (en) * 2022-03-28 2023-10-05 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (en) 1984-05-12 1985-12-11 FISONS plc Novel pharmaceutically useful pyrimidines
ATE135699T1 (de) 1986-01-13 1996-04-15 American Cyanamid Co 4,5,6-substituierte 2-pyrimidinamine
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5612340A (en) * 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
BR9407799A (pt) 1993-10-12 1997-05-06 Du Pont Merck Pharma Composição de matéria método de tratamento e composição farmaceutica
IL112290A (en) 1994-01-12 1999-01-26 Novartis Ag Transformed aryl and the troiryl pyrimidines and herbicides containing them
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds

Also Published As

Publication number Publication date
CA2401748A1 (en) 2001-10-04
NZ521068A (en) 2005-04-29
WO2001072745A1 (en) 2001-10-04
JP2003528872A (ja) 2003-09-30
CN1420884A (zh) 2003-05-28
AU4262901A (en) 2001-10-08
GB2361236A (en) 2001-10-17
US20020019404A1 (en) 2002-02-14
EP1274705A1 (en) 2003-01-15
HUP0300382A2 (hu) 2003-06-28
US6699854B2 (en) 2004-03-02
GB2361236B (en) 2002-04-24
US6531479B2 (en) 2003-03-11
US20030149057A1 (en) 2003-08-07
GB0107758D0 (en) 2001-05-16
IL151946A0 (en) 2003-04-10
CN100355751C (zh) 2007-12-19
AU2001242629B2 (en) 2005-08-11
JP5074653B2 (ja) 2012-11-14

Similar Documents

Publication Publication Date Title
HUP0300382A3 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
HUP0400384A3 (en) Benzamidine derivative and pharmaceutical compositions containing them and their use
GC0000307A (en) Pyrimidone compounds and pharmaceutical composition containing them
IL156354A0 (en) Pyridoindole derivatives and pharmaceutical compositions containing the same
HK1061037A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0400529A3 (en) Use of chlorpromazine and pentamidine for preparation of pharmaceutical compositions for the treatment of neoplastic disorders
HUP0303103A3 (en) Fused pyrrolocarbazoles, pharmaceutical compositions containing them and use of the compounds
IL156558A0 (en) Novel quinuclidine derivatives and medicinal compositions containing the same
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
HUP0302337A3 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
IL155196A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
IL151952A0 (en) Aminopyridine derivatives and pharmaceutical compositions containing the same
HUP0301577A3 (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
HUP0200831A2 (en) Novel pharmaceutical composition containing amoxycillin and its use
HUP0400784A3 (en) Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
HUP0301452A3 (en) Pharmaceutical composition containing photochemotherapeutic agent and mucoadhesive agent and its use
HUP0700086A2 (en) 2-aminopyridine compounds, use thereof as drugs and pharmaceutical compositions containing them
HUP0300798A3 (en) Substituted-triazolopyrimidines and their use as anticancer agents and pharmaceutical compositions containing them
HU9901570D0 (en) Use of nanodispersions in pharmaceutical compositions
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
PL354315A1 (en) Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides
HUP0302455A3 (en) Combination pharmaceutical compositions containing amplodipine and benazepril and their use
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees